Monopar Therapeutics Inc Cash Flow-to-Debt Ratio
Monopar Therapeutics Inc cash flow-to-debt ratio. Monopar Therapeutics Inc (MNPR) has a Cash Flow-to-Debt Ratio of -787.48x as of June 2026, meaning its operating cash flow of $-3.25 Billion could theoretically repay -787% of its total liabilities ($4.12 Million) in one year. See MNPR financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Monopar Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of Monopar Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for Monopar Therapeutics Inc across 11 annual periods. Also explore Monopar Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Monopar Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Monopar Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Monopar Therapeutics Inc. For the full cash flow conversion analysis, see MNPR cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.22x | $-12.20 Million | $2.89 Million | ▼ -246.4% |
| 2024 | -1.22x | $-6.40 Million | $5.25 Million | ▲ +72.7% |
| 2023 | -4.47x | $-7.86 Million | $1.76 Million | ▼ -94.1% |
| 2022 | -2.30x | $-7.23 Million | $3.14 Million | ▲ +50.2% |
| 2021 | -4.63x | $-7.32 Million | $1.58 Million | ▼ -16.8% |
| 2020 | -3.96x | $-4.66 Million | $1.18 Million | ▲ +4.9% |
| 2019 | -4.17x | $-3.02 Million | $724.16K | ▲ +42.3% |
| 2018 | -7.23x | $-2.89 Million | $399.55K | ▲ +14.2% |
| 2017 | -8.42x | $-2.63 Million | $311.87K | ▲ +54.5% |
| 2016 | -18.52x | $-1.19 Million | $64.51K | ▼ -114.9% |
| 2015 | -8.62x | $-636.33K | $73.84K | — |